Gladstone Institutional Advisory LLC Has $1.10 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Gladstone Institutional Advisory LLC trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.8% during the fourth quarter, Holdings Channel reports. The firm owned 13,555 shares of the biopharmaceutical company’s stock after selling 252 shares during the period. Gladstone Institutional Advisory LLC’s holdings in Gilead Sciences were worth $1,098,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Altfest L J & Co. Inc. bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $210,000. Federated Hermes Inc. raised its stake in shares of Gilead Sciences by 4.9% in the fourth quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock valued at $306,814,000 after acquiring an additional 175,925 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Gilead Sciences by 1.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company’s stock valued at $589,873,000 after acquiring an additional 87,482 shares during the last quarter. Wetzel Investment Advisors Inc. bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $74,000. Finally, ARGA Investment Management LP raised its stake in shares of Gilead Sciences by 6.2% in the fourth quarter. ARGA Investment Management LP now owns 635,058 shares of the biopharmaceutical company’s stock valued at $51,446,000 after acquiring an additional 37,069 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently issued reports on GILD. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. UBS Group dropped their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective for the company in a research report on Wednesday, April 24th. Maxim Group dropped their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Wednesday, May 1st. Finally, Wells Fargo & Company dropped their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research report on Monday, March 4th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $83.69.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $67.29 on Wednesday. The firm has a fifty day moving average of $68.93 and a two-hundred day moving average of $74.75. The stock has a market capitalization of $83.83 billion, a price-to-earnings ratio of 186.92, a PEG ratio of 1.37 and a beta of 0.22. Gilead Sciences, Inc. has a 52 week low of $64.33 and a 52 week high of $87.86. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. During the same quarter in the previous year, the business earned $1.37 EPS. The firm’s revenue was up 5.3% on a year-over-year basis. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.58%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the transaction, the insider now owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.29% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.